Longevity
Alzheimer's risk gene CASS4 directs immune cells to compress toxic plaques, mouse study finds
By Life and Health Today Staff, . Life and Health Today.
A gene that large genetic studies have repeatedly flagged as a risk factor for Alzheimer's disease works not inside neurons, as researchers had assumed, but inside microglia, the brain's resident immune cells. That is the central finding from a team at the University of Virginia School of Medicine, published in the Journal of Experimental Medicine.
Microglia are the central nervous system's cleanup specialists. Under healthy conditions they patrol brain tissue continuously, and when toxic amyloid-beta protein, the kind that accumulates in Alzheimer's disease, begins to clump into plaques, microglia migrate toward the deposits, form a dense wall around them, and physically compress the material into tight, contained bundles. That compaction matters: it keeps neurotoxic fragments from drifting outward and damaging nearby synapses, the connection points between neurons.
What CASS4 does, and what happens when it fails
The gene in question, CASS4 (Cas Scaffold Protein Family Member 4), had been identified by genome-wide association studies, large scans of human DNA that look for variants more common in people who develop a disease, as a significant risk locus for late-onset Alzheimer's. What nobody had established was where in the brain it acted or what it actually did there.
Researchers led by Dr. John Lukens, director of the University of Virginia's Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases, disrupted CASS4 function in mice engineered to develop amyloid pathology, a strain called 5xFAD. When the gene was knocked out in those mice, microglia lost their ability to form protective barriers around amyloid deposits. Plaques grew in diffuse, uncontained patterns, exposing wider areas of surrounding tissue to toxic protein fragments. In those mouse models, the result was accelerated synaptic damage, neuronal loss, and faster cognitive decline.
A phosphoproteomic analysis of purified microglia from those mice, a technique that maps which proteins in a cell are being switched on or off by chemical tags, showed marked disruption of focal adhesion signaling after CASS4 was deleted, according to the paper published through PubMed Central. Focal adhesions are the molecular anchors that let a cell grip a surface and move, which is exactly what microglia need to do when they migrate toward a plaque and press against it.
"These findings break new ground in our understanding of how this genetic risk factor contributes to Alzheimer's disease," Dr. Lukens said, as quoted by Neuroscience News. The published paper adds that defective CASS4 activity may eventually serve as an early biomarker for Alzheimer's risk, and that therapies aimed at restoring its function could represent an immunotherapeutic direction for neurodegenerative disease. Those are possibilities the authors raise, not outcomes that have been tested in people.
What the research does and does not establish
Everything described above was observed in mice. Mouse models of Alzheimer's have a long history of producing findings that do not replicate in human trials, so the distance between this result and a clinical application is real.
What the study does establish is a plausible biological mechanism: CASS4 appears to regulate the focal adhesion machinery that microglia use to physically engage with plaques. That is a more specific and testable explanation than the field had before, and it points toward the immune system rather than neurons as the site where this particular genetic risk plays out.
More than six million Americans are currently living with Alzheimer's disease, according to Neuroscience News, citing the University of Virginia. Whether targeting CASS4 in microglia could slow or modify the disease in people is a question that would require human trials to answer. None have been reported yet. If you are weighing what this means for your own situation, that conversation belongs with a clinician who knows your history.
Source: https://neurosciencenews.com/cass4-gene-microglia-alzheimers-32404/
Life & Health Today provides information for educational purposes only, not medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional.